Androgen Receptor Antagonist
Each softgel capsule contains 40mg enzalutamide
For the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- For the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
The recommended dose is 160 mg Enzalutamide (Xtandi®) (four 40 mg capsules) as a single oral daily dose.
Hypersensitivity to enzalutamide or to any of its excipients.
Women who are or may become pregnant.
Box of 112’s softgel capsules (4 capsule per pouch)